Maker Of EpiPen To Sell Generic Version For Half The Price : Shots - Health News Mylan's move comes amid pressure from consumers and Congress to lower the allergy drug's price. In less than 10 years, the price has risen from about $100 to more than $600 for an injector two-pack.
NPR logo

Maker Of EpiPen To Sell Generic Version For Half The Price

  • Download
  • <iframe src="https://www.npr.org/player/embed/491797051/491848114" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Maker Of EpiPen To Sell Generic Version For Half The Price

Maker Of EpiPen To Sell Generic Version For Half The Price

  • Download
  • <iframe src="https://www.npr.org/player/embed/491797051/491848114" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

ROBERT SIEGEL, HOST:

The maker of the EpiPen is bowing to public pressure. It plans to sell a generic version of the allergy drug for $300. That's half its current price. As NPR's Alison Kodjak reports, the public outrage could translate into lower prescription drug prices overall.

ALISON KODJAK, BYLINE: EpiPens are used to stop life-threatening allergic reactions. Consumers have been growing angry as EpiPen's maker, Mylan, boosted the price for a two-pack from $100 to $600 in six years. Caleb Alexander is co-chair of the Center for Drug Safety and Effectiveness at Johns Hopkins in Baltimore.

CALEB ALEXANDER: There's nothing that's forcing Mylan to produce a generic version of their branded product, but they're doing so because they argue that this is the best means of addressing the public outrage over the high cost of the EpiPen.

KODJAK: The controversy is following a familiar cycle of outrage over the rising drug prices. Consumers complain. Lawmakers threaten hearings and new regulations, then the company backs down. Alexander says this incident could put the brakes on drastic drug price increases.

ALEXANDER: I think we can only hope that this latest brouhaha helps force systemic change.

KODJAK: He says companies may see that raising prices is risky to their reputations, or the Food and Drug Administration could speed up approvals for generic drugs in cases where prices are rising fast. Alison Kodjak, NPR News.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.